DCTH vs MDT
DCTH: Delcath Systems is an interventional oncology company providing a proprietary drug/device combination for liver-directed cancer treatment. MDT: Medtronic is a global healthcare technology leader dedicated to alleviating pain, restoring health, and extending life through innovative medical devices and digital solutions.
Side-by-side fundamentals
| Metric | DCTH | MDT | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $14.76 | $94.63 | |
| Market cap | $512M | $121.0B | |
| P/E as of 2026-10-20 | n/a | 23.31 | |
| PEG as of 2026-10-20, 3-year EPS CAGR to FY2026 | n/a | 2.39 | |
| Net margin | +3.2% | +13.2% | MDT higher |
| Gross margin FY2025, SEC XBRL | +86.2% | n/a | |
| Operating margin | +0.8% | +17.8% | MDT higher |
| ROE | +2.4% | +9.7% | MDT higher |
| ROA | +2.2% | +5.2% | MDT higher |
| Debt / equity filed borrowings incl. finance leases, balance sheet 2026-07-31 | n/a | 0.56 | |
| Revenue growth (YoY) | +129.1% | +8.4% | DCTH higher |
| Revenue CAGR (3y) SEC XBRL | +215.3% | +5.2% | DCTH higher |
| Dividend yield as of 2026-09-03 | n/a | +3.1% | |
| Dividend streak (yrs) SEC XBRL | 0 | 14 | MDT higher |
| Beta as of 2026-09-03 | 1.37 | 0.35 | |
| 1-year return as of 2026-10-20 close | +29.2% | -1.3% | DCTH higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.